Who is affected by this change?

This affects Independence Blue Cross Endocrinology, General Surgery providers on Commercial plans.

When does this change take effect?

This change is effective Mar 5, 2025.

Back to dashboard

CommercialCoverageLow impact

11.04.01e, Islet Cell Transplantation, including use of Donislecel-jujn (Lantidra)

Independence Blue Cross·Endocrinology, General Surgery·Medical Policy

Effective date

Mar 5, 2025

We identified it

Jun 19, 2026

Days to comply

—

Summary

Insurance policy for islet cell transplantation including the new drug Donislecel-jujn (Lantidra) has been updated. This is a very specialized diabetes treatment policy that will be reissued effective March 5, 2025.

Action Required

Action needed

By March 5, 2025: Billing team should review the updated islet cell transplantation policy at the provided URL to understand any changes to coverage criteria or documentation requirements for Donislecel-jujn (Lantidra) procedures. This affects only practices performing specialized diabetes transplant procedures.

Related policy hubs

Independence Blue Cross policies Endocrinology General Surgery